

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 143873961 US

Date of Deposit: April 1, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to : Assistant Commissioner for Patents, Office of Initial Patent Examination, Washington, D.C. 20231.

*Judy Bridgewater*  
Judy Bridgewater

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

John SIDNEY, et al.

Serial No.: 09/935,476

Filing Date: August 22, 2001

For: SUBUNIT VACCINES WITH A2  
SUPERMOTIFS

Examiner: To be Assigned

Group Art Unit: 1644

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR  
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed February 24, 2003, for which a response is due on March 24, 2003. Accordingly, a petition and request for extension of time from March 24, 2003 to April 24, 2003 accompany this response.

Please enter the following substitute Sequence Listing and remarks.

In the Sequence Listing

Please replace the paper copy and the computer-readable form (CRF) copy of the Sequence Listing submitted for this application, on February 14, 2002, with the substitute sheets of the sequence listing, pages 1-73, and the CRF copy submitted herewith.

## REMARKS

The reasons for noncompliance, as attached to The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, indicate that the sequences depicted in Figure 1 need to be in CRF and paper copy of the sequence listing. Applicants assert that there are no sequences disclosed in Figure 1. Applicants have corrected the sequence listing to include the sequences disclosed in Figures 2, 5, 6, 7, 8, 9, and the sequences disclosed in the claims submitted in the preliminary amendment and filed with the Office on August 14, 2002. It is respectfully submitted that the sequence listing is now in compliance with 37 C.F.R. §1.821-1.825.


Applicants submit herewith a substitute paper copy of the sequence listing, pages 1-73, and substitute CRF copy of the sequence listing, in compliance with 37 C.F.R. §1.821(c), and §1.825(a) and (b). The substitute sheets of the sequence listing and the CRF copy submitted herewith, in accordance with 37 C.F.R. §1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 399632002920. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 1, 2003

By:

  
\_\_\_\_\_  
Bruce Grant.  
Registration No. 47,608  
Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-7962  
Facsimile: (858) 720-5125